Intelligence Profile
Research Papers
Vibegron, a medication used for overactive bladder (OAB), has been studied in various research papers and clinical trials.
A systematic review and network meta-analysis compared vibegron, mirabegron, and tolterodine, focusing on safety and efficacy for OAB patients. Though specific sample sizes aren't mentioned, meta-analyses generally pool data from multiple studies, offering robust insights. This review suggested that vibegron could be a comparably effective alternative with a favorable safety profile.
Another study reviewed treatments for refractory monosymptomatic enuresis in children, though vibegron's role specifically in enuresis remains less detailed, indicating a need for further exploration in pediatric cases.
A narrative review discussed managing persistent OAB symptoms in men with benign prostatic hyperplasia, mentioning vibegron as a therapeutic option. Despite limited specific data, this highlights the broad applicability of vibegron beyond typical OAB management.
In pediatric cases, a case report involving vibegron addressed anticholinergic-resistant neurogenic lower urinary tract dysfunction post-spinal cord amputation. This suggests potential uses in complex pediatric urological conditions.
Clinical trials further explore vibegron's potential. A phase 3 trial (NCT06987383) aims to study its effects on energy and resilience in aging, though not yet recruiting. An ongoing phase 2/3 study (NCT05491525) investigates its long-term safety in children with neurogenic detrusor overactivity on clean intermittent catheterization. A phase 4 trial (NCT05806164) compares vibegron with onabotulinumtoxinA for urgency urinary incontinence, actively recruiting participants to assess efficacy in real-world scenarios.
A terminated phase 1 trial (NCT01500382) explored the pharmacokinetics and pharmacodynamics of vibegron in women with OAB but did not reach completion. Meanwhile, a completed phase 3 study (NCT03583372) examined the long-term safety and tolerability in OAB patients.
Overall, vibegron shows promise across various demographics for managing OAB, though further targeted research would solidify these findings.
Disclaimer: This summary is for informational purposes only and should not be taken as medical advice. Always consult healthcare professionals for medical concerns.